WO2020114358A1 - Anticorps cd19 et ses applications - Google Patents

Anticorps cd19 et ses applications Download PDF

Info

Publication number
WO2020114358A1
WO2020114358A1 PCT/CN2019/122486 CN2019122486W WO2020114358A1 WO 2020114358 A1 WO2020114358 A1 WO 2020114358A1 CN 2019122486 W CN2019122486 W CN 2019122486W WO 2020114358 A1 WO2020114358 A1 WO 2020114358A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
antibody
amino acid
antigen
acid sequence
Prior art date
Application number
PCT/CN2019/122486
Other languages
English (en)
Chinese (zh)
Inventor
董军纪
陈超
于婷婷
徐乐
危喜玲
李志广
李想
曾怡
李少燕
陈小锋
李文佳
Original Assignee
广东东阳光药业有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广东东阳光药业有限公司 filed Critical 广东东阳光药业有限公司
Publication of WO2020114358A1 publication Critical patent/WO2020114358A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Definitions

  • the present application relates to the field of biomedicine, in particular to an antibody or antigen-binding fragment that specifically binds to CD19 protein.
  • B lymphocyte antigen CD19 also known as CD19 molecule (differentiation cluster 19).
  • CD19 is expressed in B cells of the germinal center and large dendritic cells in the follicular dendritic cells, mantle cells, and T cell regions between follicles.
  • CD19 plays two main roles in human B cells, one is to act as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane, and the other is to act within the CD19/CD21 complex to lower the threshold of the B cell receptor signaling pathway .
  • CD19 protein is a target protein that exists stably on the surface of B lymphocytes. It exists in all stages of B cell maturation.
  • CD19 has become an important target for the treatment of hematoma-related tumors.
  • CD19 antibodies have low specificity and limited tumor suppressive capacity, so it is urgent to develop new anti-CD19 drugs for new drug development.
  • the present application provides an antibody or antigen-binding fragment that specifically binds to CD19 and uses thereof.
  • the present application also provides a fusion protein comprising the antibody or antigen-binding fragment thereof, a nucleic acid molecule encoding the antibody or antigen-binding protein thereof, a vector containing the nucleic acid molecule, a cell containing the vector or the nucleic acid molecule, etc. .
  • the anti-CD19 antibody provided in this application has one or more of the following properties: 1) can specifically bind to the CD19 protein; 2) has different affinity characteristics for different epitopes of the CD19 protein; 3) has a good targeted killing effect ; 4) has higher stability; 5) has higher purity; 6) can be used to treat cancer.
  • the present application provides an antibody, antigen-binding fragment or variant thereof that binds to CD19 protein with an IC 50 value of 3.5 ⁇ g/ml or lower.
  • the antibody is selected from any one of the group consisting of monoclonal antibodies, single chain antibodies, chimeric antibodies, murine antibodies, and humanized antibodies.
  • the antigen-binding fragment is selected from the group consisting of: Fab, Fab', F(ab)2, F(ab')2, Fv, and scFv.
  • the variant is selected from the group consisting of: 1) a protein or polypeptide substituted, deleted, or added with one or more amino acids in the antibody or the antigen-binding fragment thereof; and 2) with The antibody or the antigen-binding fragment of the protein or polypeptide has more than 90% sequence homology.
  • the present application provides an antibody, antigen-binding fragment or variant thereof, which competes with a reference antibody for binding to the CD19 protein
  • the reference antibody comprises light Chain variable region and heavy chain variable region
  • the light chain variable region of the reference antibody comprises LCDR1-3
  • the amino acid sequence of the LCDR1 is selected from the amino acid sequence shown in any one of the following group: SEQ ID NO : 4 and SEQ ID NO: 18
  • the amino acid sequence of the LCDR2 is selected from the amino acid sequences shown in any of the following groups: SEQ ID NO: 5 and SEQ ID NO: 19
  • the LCDR3 amino acid sequence is selected from The amino acid sequence shown in any of the following group: SEQ ID NO: 6 and SEQ ID NO: 20
  • the heavy chain variable region of the reference antibody comprises HCDR1-3
  • the amino acid sequence of the HCDR1 is selected from The amino acid sequence shown in any one of the groups: SEQ ID NO: 7, SEQ ID NO: 21 and SEQ ID NO: 32; the amino acid sequence of the HC
  • the amino acid sequence of the light chain variable region of the reference antibody is selected from the amino acid sequences shown in any of the following groups: SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO :46
  • the amino acid sequence of the heavy chain variable region of the reference antibody is selected from the amino acid sequences shown in any of the following groups: SEQ ID NO: 48, SEQ ID NO: 50, and SEQ ID NO: 52.
  • the antibody 3.5 ⁇ g / ml or less of IC 50 values combined with the CD19 protein.
  • the antibody is selected from any one of the group consisting of monoclonal antibodies, single chain antibodies, chimeric antibodies, murine antibodies, and humanized antibodies.
  • the antigen-binding fragment is selected from the group consisting of: Fab, Fab', F(ab)2, F(ab')2, Fv, and scFv.
  • the variant is selected from the group consisting of: 1) a protein or polypeptide substituted, deleted, or added with one or more amino acids in the antibody or the antigen-binding fragment thereof; and 2) with The antibody or the antigen-binding fragment of the protein or polypeptide has more than 90% sequence homology.
  • the present application provides an antibody, antigen-binding fragment or variant thereof
  • the antibody, antigen-binding fragment or variant thereof comprises LCDR1
  • the LCDR1 comprises an amino acid selected from any one of the following group Sequence: SEQ ID NO: 4 and SEQ ID NO: 18.
  • it comprises LCDR2
  • the LCDR2 comprises an amino acid sequence selected from any one of the group consisting of SEQ ID NO: 5 and SEQ ID NO: 19.
  • it includes LCDR3
  • the LCDR3 includes an amino acid sequence selected from any one of the group consisting of SEQ ID NO: 6 and SEQ ID NO: 20.
  • it comprises a light chain variable region VL
  • the light chain variable region VL comprises an amino acid sequence selected from any one of the group consisting of SEQ ID NO: 42, SEQ ID NO: 44 And SEQ ID NO: 46.
  • the HCDR1 comprises an amino acid sequence selected from any one of the group consisting of SEQ ID NO: 7, SEQ ID NO: 21 and SEQ ID NO: 32.
  • it comprises HCDR2, and the HCDR2 comprises an amino acid sequence selected from any one of the group consisting of SEQ ID NO: 8, SEQ ID NO: 22, and SEQ ID NO: 33.
  • it comprises HCDR3, and the HCDR3 comprises an amino acid sequence selected from any one of the group consisting of SEQ ID NO: 9 and SEQ ID NO: 23 and SEQ ID NO: 34.
  • it comprises a heavy chain variable region VH, and the heavy chain variable region VH comprises an amino acid sequence selected from any one of the group consisting of SEQ ID NO: 48, SEQ ID NO: 50 And SEQ ID NO: 52.
  • the antibody or antigen-binding fragment thereof is scFv.
  • the scFv comprises an amino acid sequence selected from any one of the group consisting of SEQ ID NO: 56, SEQ ID NO: 58 and SEQ ID NO: 60.
  • the antibody 3.5 ⁇ g / ml or less of IC 50 values combined with the CD19 protein.
  • the antibody is selected from any one of the group consisting of monoclonal antibodies, single chain antibodies, chimeric antibodies, murine antibodies, and humanized antibodies.
  • the antigen-binding fragment is selected from the group consisting of: Fab, Fab', F(ab)2, F(ab')2, Fv, and scFv.
  • the variant is selected from the group consisting of: 1) a protein or polypeptide substituted, deleted, or added with one or more amino acids in the antibody or the antigen-binding fragment thereof; and 2) with The antibody or the antigen-binding fragment of the protein or polypeptide has more than 90% sequence homology.
  • the CD19 protein is mouse CD19 protein.
  • the present application provides a fusion protein comprising the antibody, antigen-binding fragment or variant thereof described herein.
  • the fusion protein is a chimeric antigen receptor.
  • the chimeric antigen receptor comprises an extracellular hinge region, a transmembrane domain, a costimulatory domain, and a CD3 ⁇ intracellular signal transduction domain.
  • the extracellular hinge region is selected from CD8 hinge or IgG4 hinge.
  • the transmembrane domain is selected from the ⁇ , ⁇ , or ⁇ chain of the T cell receptor, CD28, CD3e, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64 , CD80, CD86, CD134, CD137 and CD154. In certain embodiments, the transmembrane domain is selected from CD8-1 or CD8-2.
  • the costimulatory domain is selected from CD27, CD28, 4-1BB, OX40, or ICOS.
  • the extracellular hinge region is selected from a CD8 hinge or an IgG4 hinge; the transmembrane domain is selected from CD8-1 or CD8-2; the co-stimulation The domain is selected from 4-1BB or OX40.
  • the N-terminus of the CD8-1 transmembrane is connected to the C-terminus of the CD8 hinge, and the C-terminus of the CD8-1 transmembrane is linked to the 4
  • the N terminal of -1BB is connected
  • the C terminal of 4-1BB is connected to the N terminal of OX40
  • the C terminal of OX40 is connected to the N terminal of CD3 ⁇ .
  • the N-terminus of the CD8-2 transmembrane is connected to the C-terminus of the IgG4 hinge, and the C-terminus of the CD8-2 transmembrane is linked to the 4
  • the N terminal of -1BB is connected
  • the C terminal of 4-1BB is connected to the N terminal of OX40
  • the C terminal of OX40 is connected to the N terminal of CD3 ⁇ .
  • the present application provides isolated one or more nucleic acid molecules that encode the antibodies, antigen-binding fragments or variants described herein, and/or that encode the fusion proteins described herein.
  • the present application provides one or more vectors, which comprise one or more nucleic acid molecules described in the present application.
  • the present application provides one or more cells comprising one or more nucleic acid molecules described herein or one or more vectors described herein.
  • the present application provides a method for preparing the antibody, antigen-binding fragment or variant thereof, and/or the fusion protein described in the present application.
  • the antigen-binding fragments or variants thereof, and/or the cells described herein are cultured under the conditions for the expression of the fusion protein described herein.
  • the methods described herein include harvesting the antibody, antigen-binding fragment or variant thereof, and/or the fusion protein.
  • the present application provides a pharmaceutical composition
  • a pharmaceutical composition comprising the antibody described herein, its antigen-binding fragment or variant, the nucleic acid molecule described herein, the vector described herein, and the application described herein Cells and/or fusion proteins described herein, and optionally pharmaceutically acceptable adjuvants.
  • the present application provides the antibody, antigen-binding fragment or variant thereof, and/or the use of the fusion protein in the preparation of a medicament for preventing or treating a disease or disorder.
  • the disease or disorder is selected from any one of the group consisting of tumors and autoimmune diseases.
  • the tumor is selected from any one of the group consisting of B-cell subtype non-Hodgkin's malignant lymphoma (NHL), Burkitt's lymphoma, multiple myeloma, pre-B Acute lymphoblastic leukemia and other malignant lung tumors derived from early B-cell precursors, common acute lymphocytic leukemia, T chronic lymphocytic leukemia, hairy cell leukemia, non-acute lymphoblastic leukemia, Fahrenheit macroglobulin blood Disease, prolymphocytic leukemia, plasmacytoma, osteosclerotic myeloma, plasmacytic leukemia, monoclonal gammopathy (MGUS), smoldering multiple myeloma (SMM), chronic multiple myeloma (IMM) ), Hodgkin's malignant lymphoma, gastric cancer, liver cancer, leukemia, kidney tumor, lung cancer, small intestine cancer, bone cancer,
  • NHL B
  • the autoimmune disease is selected from any one of the group consisting of rheumatoid arthritis, multiple sclerosis, and CD19 + leukemia.
  • the present application provides a method for inhibiting the biological activity of CD19 protein, which comprises administering the antibody, antigen-binding fragment or variant thereof, the nucleic acid molecule, the carrier, the carrier Cells and/or the fusion protein.
  • the application provides the antibody, antigen-binding fragment or variant thereof, the nucleic acid molecule, the carrier, the cell and/or the fusion protein described in the application Application of reagents for detecting tumors.
  • Figure 1 shows the ELISA activity detection results of the CD19 antibody described in this application.
  • Figure 2 shows the results of the CD19 antibody flow cytometry assay described in this application.
  • Figure 3 shows the detection results of the CD19 antibody Western blot method described in this application.
  • Fig. 4 shows the results of the flow cytometry detection of the CD19 antibody described in this application at different concentrations.
  • FIG. 5 shows a schematic diagram of the CAR structure constructed in the embodiment of the present application.
  • Figure 6 shows the test results of anti-CD19CAR-T positive rate.
  • the present application provides an antibody that can specifically bind to CD19 protein, which can specifically bind to CD19 protein and possess different affinity characteristics for different epitopes of CD19.
  • the CD19 antibody has good targeted killing effect, higher stability, and higher purity.
  • the CD19 antibody can be used to treat cancer.
  • an antibody generally refers to a polypeptide molecule that can specifically recognize and/or neutralize a specific antigen.
  • an antibody may include an immunoglobulin composed of at least two heavy (H) chains and two light (L) chains connected to each other by a disulfide bond, and include any molecule that includes an antigen binding portion thereof.
  • the term “antibody” includes monoclonal antibodies, antibody fragments, or antibody derivatives, including but not limited to human antibodies, humanized antibodies, chimeric antibodies, single domain antibodies (eg, dAbs), single chain antibodies (eg, scFv), And antibody fragments that bind to the antigen (eg, Fab, Fab' and (Fab) 2 fragments).
  • the term “monoclonal antibody” (monoclonal antibody) (mAb) generally refers to an antibody produced by only one type of immune cell, and can also be produced by the fusion of the immune cell that makes this antibody and cancer cells Hybridoma cells are produced.
  • the term “single chain antibody” (single chain antibody) (sFv) generally refers to an antibody composed of an antibody heavy chain variable region and a light chain variable region connected by a linker. ScFv can better retain its affinity for antigen, and has the characteristics of small molecular weight, strong penetration and weak antigenity.
  • humanized antibody generally refers to an antibody re-expressed by murine monoclonal antibody modified by gene cloning and DNA recombination technology, most of its amino acid sequence is replaced by human sequence, and the parent mouse monoclonal is basically retained The affinity and specificity of the antibody, which reduces its heterogeneity, is beneficial to the human body.
  • chimeric antibody generally refers to an antibody composed of the V region gene of a murine antibody and the C region gene of a human antibody, because it reduces the components of the murine origin, thereby reducing the murine origin Adverse reactions caused by sexual antibodies and help improve efficacy.
  • murine antibody generally refers to the fusion of B cells derived from immunized mice with myeloma cells, and then selecting a mouse hybrid fusion cell that can both wirelessly propagate and secrete antibodies, and Screening, antibody preparation and purification.
  • antibody also includes all recombinant forms of antibodies, such as antibodies expressed in prokaryotic cells as well as any antibody fragments and derivatives thereof that bind to antigens described herein.
  • Each heavy chain may be composed of a heavy chain variable region (VH) and a heavy chain constant region.
  • Each light chain may be composed of a light chain variable region (VL) and a light chain constant region.
  • VH and VL regions can be further divided into hypervariable regions called complementarity determining regions (CDRs), which are interspersed in more conserved regions called framework regions (FR).
  • CDRs complementarity determining regions
  • FR framework regions
  • Each VH and VL may be composed of three CDRs and four FR regions, and they may be arranged in the following order from the amino terminus to the carboxy terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.
  • the variable regions of the heavy and light chains contain binding domains that interact with the antigen.
  • the constant region of the antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (eg, effector cells) and the first component of the classical complement system (Clq).
  • antibody binding fragment generally refers to one or more fragments of an antibody that perform the function of specifically binding an antigen.
  • the antigen-binding function of an antibody can be achieved by the full-length fragment of the antibody.
  • the antigen-binding function of an antibody can also be achieved by the following fragments: (1) Fab fragment, that is, a monovalent fragment composed of VL, VH, CL, and CH domains; (2) F(ab') 2 fragment, including A bivalent fragment of two Fab fragments connected by a disulfide bond at the hinge region; (3) Fd fragments composed of VH and CH domains; (4) Fv fragments composed of VL and VH domains of one arm of an antibody; (5) A dAb fragment composed of VH domains (Ward et al., (1989) Nature 341: 544-546); (6) the isolated complementarity determining region (CDR) and (7) two optionally connected by a linker A combination of three or more separate CDRs.
  • CDR complementarity determining region
  • the "antigen binding portion” may also include an immunoglobulin fusion protein, the fusion protein comprising a binding domain selected from: (1) a binding domain polypeptide fused to an immunoglobulin hinge region polypeptide; (2) CH2 constant region of the immunoglobulin heavy chain fused to the hinge region; and (3) CH3 constant region of the immunoglobulin heavy chain fused to the CH2 constant region.
  • an antibody specifically binding to CD19 protein provided by the present application, wherein the antibody or antigen-binding fragment thereof is selected from the group consisting of Fab, scFv, Fab', F(ab)2, F(ab')2 and dAb .
  • CD19 protein generally refers to a transmembrane glycoprotein unique to the B cell line of about 95 kDa that is mainly expressed in early B cells.
  • CD19 protein is expressed in normal and malignant B lymphocytes and is regarded as the most reliable surface marker during B cell development.
  • the CD19 protein may be a human CD19 protein.
  • the human CD19 protein expressed in the present application may include the amino acid sequence shown in NCBI accession number AAB60697.
  • the CD19 protein may be a CD19 recombinant protein, and the recombinant protein may be the extracellular region of the CD19 protein.
  • the CD19 recombinant protein may be ab234966 of abcam, a protein with amino acid sequence numbers from 20 to 291.
  • fusion protein is also referred to as chimeric protein (chimeric protein), and usually refers to the expression product of two genes obtained by DNA recombination technology after recombination.
  • Fusion protein technology is a purposeful gene fusion and protein expression method for obtaining a large number of standard fusion proteins. Using fusion protein technology, it is possible to construct and express novel target proteins with multiple functions. Translation of the fusion gene produces a single or multiple polypeptides with the functional properties of each original protein of the derivat.
  • the recombinant fusion protein artificially produced by recombinant DNA technology can be used for biological research or treatment.
  • the chimera or chimera generally represents a fusion protein made of polypeptides with different functions or physicochemical characteristics.
  • the fusion protein may include a chimeric antigen receptor formed by fusing the antigen-binding region scFv, CD3 ⁇ chain or intracellular part of the antibody, which may include tumor-associated antigen-binding region, extracellular hinge region, transmembrane region and other domains.
  • the tumor-associated antigen-binding region can be derived from the antigen-binding region of an antibody, such as scFv.
  • chimeric antigen receptor is a fusion protein of the variable region of a single chain antibody and a T cell signaling molecule. It allows T cells to recognize specific antigens in a non-MHC-restricted manner and exert a killing effect.
  • single-chain antibody may be an antibody composed of the heavy chain variable region and the light chain variable region connected by a linker peptide.
  • CAR is the core component of chimeric antigen receptor T cells (CAR-T), which may include CD19 binding domain, transmembrane domain, costimulatory domain and intracellular signal transduction domain.
  • transmembrane domain generally refers to a domain in CAR that passes through a cell membrane, which is connected to an intracellular signal transduction domain and plays a role in transmitting signals.
  • costimulatory domain generally refers to an intracellular domain that can provide an immunocostimulatory molecule that is a cell surface molecule required for an effective response of lymphocytes to an antigen.
  • intracellular signaling domain generally refers to a component of CAR signaling located in a cell, which includes a signaling domain and a domain that specifically binds to the receptor component, for example: It can be selected from CD3 ⁇ intracellular domain, CD28 intracellular domain, 4-1BB intracellular domain and OX40 intracellular domain.
  • variants related to antibodies means in the present application that it has been substituted by at least 1, such as 1-30, or 1-20 or 1-10, such as 1 or 2 or 3 or 4 or 5 amino acids, Antibodies with deletion and/or insertion that have a target antibody region of amino acid changes (eg, heavy chain variable region or light chain variable region or heavy chain CDR region or light chain CDR region), where the variant substantially retains the antibody before the change Molecular biological properties.
  • this application encompasses any antibody variants described in this application.
  • the antibody variant retains at least 60%, 70%, 80%, 90%, or 100% of the biological activity (eg, antigen binding capacity) of the pre-altered antibody.
  • the change does not cause the antibody variant to lose its binding to the antigen, but optionally can impart properties such as increased antigen affinity and different effector functions.
  • the heavy chain variable region or light chain variable region, or each CDR region of an antibody may be changed individually or in combination.
  • the amino acid changes in one or more or all three heavy chain CDRs are no more than 1, 2, 3, 4, 5, 6, 6, 7, 8, 9 Or 10.
  • the amino acid change may be an amino acid substitution, for example, it may be a conservative substitution.
  • the antibody variant has at least 80%, 85%, 90%, or 95% or 99% or higher amino acid identity over the antibody sequence region of interest.
  • the term "isolated” generally refers to an antibody that has been separated from components in its natural environment.
  • the antibody is purified to greater than 95% or 99% purity by, for example, electrophoresis (eg, SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (eg, ion exchange or Reverse phase HPLC).
  • electrophoresis eg, SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis
  • chromatography eg, ion exchange or Reverse phase HPLC
  • nucleic acid molecule generally refers to an isolated form of nucleotides, deoxyribonucleotides or ribonucleotides of any length, isolated from its natural environment or artificially synthesized, or analogs thereof.
  • the nucleic acid molecules described in this application may be isolated. For example, it can be produced or synthesized by: (i) amplified in vitro, such as polymerase chain reaction (PCR) amplification, (ii) cloned and recombinantly produced, (iii) purified , Such as by enzyme digestion and gel electrophoresis fractionation, or (iv) synthetic, for example by chemical synthesis.
  • PCR polymerase chain reaction
  • the isolated nucleic acid is a nucleic acid molecule prepared by recombinant DNA technology.
  • nucleic acids encoding the antibodies or antigen-binding fragments thereof can be prepared by a variety of methods known in the art. These methods include, but are not limited to, the use of restriction fragment manipulation or the use of synthetic oligonucleotides Overlapping extension PCR, specific operations can be found in Sambrook et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; and Ausube et al. Current Protocols Molecular Biology, Greene Publishing and Wiley-Interscience, New York, 1993.
  • the term "vector” generally refers to a nucleic acid molecule capable of self-replication in a suitable host to transfer the inserted nucleic acid molecule into and/or between host cells.
  • the vector may include a vector mainly used for inserting DNA or RNA into a cell, a vector mainly used for replicating DNA or RNA, and a vector mainly used for expression of transcription and/or translation of DNA or RNA.
  • the carrier also includes carriers having multiple functions described above.
  • the vector may be a polynucleotide capable of being transcribed and translated into a polypeptide when introduced into a suitable host cell. Generally, by culturing a suitable host cell containing the vector, the vector can produce the desired expression product.
  • the vector may also contain other genes, such as marker genes that allow selection of the vector in appropriate host cells and under appropriate conditions.
  • the vector may also contain expression control elements that allow the coding region to be correctly expressed in a suitable host.
  • control elements are well known to those skilled in the art. For example, they may include promoters, ribosome binding sites, enhancers, and other control elements that regulate gene transcription or mRNA translation.
  • the expression control sequence is an adjustable element.
  • the specific structure of the expression control sequence may vary according to the function of the species or cell type, but usually contains 5'untranscribed sequences and 5'and 3'untranslated sequences involved in transcription and translation initiation, such as TATA box, Cap sequence, CAAT sequence, etc.
  • the 5' non-transcriptional expression control sequence may comprise a promoter region, and the promoter region may comprise a promoter sequence for transcriptional control of functionally linked nucleic acids.
  • the term "cell” generally refers to an individual cell or cell that can express the antibody, antigen-binding fragment or variant thereof described herein, and can or already contains a plasmid or vector including the nucleic acid molecule described herein Line or cell culture.
  • the cells may be prokaryotic cells (such as E. coli) or eukaryotic cells (such as yeast cells, COS cells, Chinese hamster ovary (CHO) cells, HeLa cells, HEK293 cells, COS-1 cells, NS0 cells or bone marrow Tumor cells).
  • the cell may be an immune cell.
  • pharmaceutically acceptable adjuvant generally refers to a pharmaceutically acceptable formulation carrier, solution, or additive that enhances the properties of the formulation.
  • additives are well known to those skilled in the art.
  • cancer generally refers to or describes the physiological condition of a mammal, which is typically characterized by unregulated cell proliferation or survival.
  • hyperproliferative diseases called cancer include, but are not limited to, solid tumors, such as occur in breast, respiratory tract, brain, reproductive organs, digestive tract, urethra, eyes, liver, skin, head and neck, thyroid, parathyroid Cancer of the glands, and their distant metastasis.
  • diseases also include lymphoma, sarcoma and leukemia.
  • breast cancer include, but are not limited to, invasive ductal carcinoma, invasive lobular carcinoma, breast ductal carcinoma in situ, and breast lobular carcinoma in situ.
  • cancers of the respiratory tract include, but are not limited to, small cell lung cancer and non-small cell lung cancer, as well as bronchial adenoma and pleural lung blastoma.
  • brain cancer include, but are not limited to, brain stem and hypothalamic keratinoma, cerebellar and cerebral astrocytoma, medulloblastoma, ependymoma, and neuroectodermal and pineal tumors.
  • Male genital tumors include but are not limited to prostate and testicular cancer.
  • Female genital tumors include but are not limited to endometrial cancer, cervical cancer, ovarian cancer, vaginal cancer and vulvar cancer, as well as uterine tumors.
  • Gastrointestinal tumors include but are not limited to anal, colon, colorectal, esophageal, gallbladder, stomach, pancreas, rectum, small intestine, and salivary gland cancers.
  • Urethral tumors include but are not limited to bladder, penis, kidney, renal pelvis, ureter, and urethral cancer.
  • Eye cancers include but are not limited to intraocular melanoma and retinoblastoma.
  • liver cancer include, but are not limited to, hepatocellular carcinoma (hepatocellular carcinoma with or without fibrous lamellar variation), cholangiocarcinoma (intrahepatic cholangiocarcinoma), and mixed hepatocellular cholangiocarcinoma.
  • Skin cancers include, but are not limited to, squamous cell carcinoma, Kaposi's sarcoma, malignant melanoma, Merkel cell skin cancer, and non-melanoma type skin cancer.
  • Head and neck cancers include but are not limited to laryngeal/ hypopharyngeal/nasopharyngeal/oropharyngeal cancers, and lips and oral cavity cancers.
  • Lymphomas include, but are not limited to, AIDS-related lymphoma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, Hodgkin's disease, and central nervous system lymphoma.
  • Sarcomas include, but are not limited to, soft tissue sarcoma, osteosarcoma, malignant fibrous histiocytoma, lymphosarcoma, and rhabdomyosarcoma.
  • Leukemias include but are not limited to acute myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, and hairy cell leukemia.
  • autoimmune disease generally refers to an autoimmune disease that refers to a disease caused by an immune response of the body to self-antigens that causes damage to its own tissues.
  • the immune system defends the body from invasion (recognition) by foreign or dangerous substances, including microorganisms, parasites, malignant tumor cells, and transplanted organs and tissues. Under normal circumstances, the immune system only reacts to foreign or dangerous substances, but does not react to antigens in its own tissues. However, sometimes there is abnormal immune function, which treats its own tissues as foreign, and produces antibodies (called autoantibodies) or immune cells to attack its own cells or tissues. This response is called an autoimmune response. It causes inflammation and tissue damage.
  • autoimmune diseases may cause autoimmune diseases, but some people produce very little autoantibodies without autoimmune diseases.
  • Common autoimmune diseases include rheumatoid arthritis, multiple sclerosis, and CD19 + leukemia. Additional diseases considered to be autoimmune include Addison's disease, polymyositis, Syndrome, progressive systemic sclerosis, multiple cases of glomerulonephritis (kidney inflammation) and some cases of infertility.
  • the term "about” generally refers to a range of 0.5%-10% above or below the specified value, for example, 0.5%, 1%, 1.5%, 2%, 2.5%, above or below the specified value 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10%.
  • the present application provides an antibody, antigen-binding fragment or variant thereof, which may be 3.5 ⁇ g/mL or less (eg, 3.5 ⁇ g/ml or less, 3.4 ⁇ g/mL or less, 3.3 ⁇ g/mL or more Low, 3.2 ⁇ g/mL or lower, 3.15 ⁇ g/mL or lower, 3.1 ⁇ g/ml or lower, 3.0 ⁇ g/mL or lower, 2.9 ⁇ g/mL or lower, 2.8 ⁇ g/mL or lower, 2.5 ⁇ g / mL or less, or 2.1 ⁇ g / mL or less) and IC 50 values with CD19 binding proteins.
  • the IC 50 value is determined by an ELISA method, and the IC 50 value may be 3.12 ⁇ g/mL or lower.
  • the antibody, antigen-binding fragment or variant thereof may be 5 ⁇ g/mL or lower (eg, 5 ⁇ g/mL or lower, 4.5 ⁇ g/mL or lower, 4 ⁇ g/mL or lower, 50 value of 3.5 ⁇ g / mL or less, 3 ⁇ g / mL or less, 2.5 ⁇ g / mL or less, 2 ⁇ g / mL or less, 1.5 ⁇ g / mL or less, 1 ⁇ g / mL or less) and an IC CD19 protein combined.
  • the IC 50 value is determined by flow cytometry, and the IC 50 value may be 5 ⁇ g/mL or less.
  • the antibody may be selected from any of the following group: monoclonal antibody, single chain antibody, chimeric antibody, murine antibody, and humanized antibody.
  • the antigen-binding fragment may be selected from the group consisting of: Fab, Fab', F(ab)2, F(ab')2, Fv, and scFv.
  • the variant may be selected from the following group: 1) One or more (eg, 1-2, 1-3) are substituted, deleted, or added to the antibody or the antigen-binding fragment thereof , 1-4, 1-5, 1-6, 1-7, 1-8, 1-9, 1-10 or more) amino acid protein or polypeptide; and 2) More than 90% (eg, at least about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97) of the antibody or the antigen-binding fragment thereof %, about 98%, about 99% or more) of sequence homology protein or polypeptide.
  • the variant has substantially the same function as the antibody and its antigen-binding fragment (for example, it can specifically bind to the CD19 protein).
  • the antibody, antigen-binding fragment or variant thereof can compete with a reference antibody for binding to the CD19 protein.
  • the reference antibody may comprise a light chain variable region and a heavy chain variable region
  • the light chain variable region of the reference antibody may comprise LCDR1-3
  • the amino acid sequence of the LCDR1 may be selected from The amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 4 and SEQ ID NO: 18
  • the amino acid sequence of the LCDR2 may be selected from the amino acid sequence shown in any one of the following group or Variants: SEQ ID NO: 5 and SEQ ID NO: 19
  • the amino acid sequence of the LCDR3 can be selected from the amino acid sequences shown in any of the following groups or variants thereof: SEQ ID NO: 6 and SEQ ID NO :20
  • the heavy chain variable region of the reference antibody may include HCDR1-3
  • the amino acid sequence of the HCDR1 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof:
  • amino acid sequence of the HCDR2 may be selected from the amino acid sequence shown in any one of the following groups or a variant thereof: SEQ ID NO: 8, SEQ ID NO: 22 And SEQ ID NO: 33; and the amino acid sequence of the HCDR3 can be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 9, SEQ ID NO: 23 and SEQ ID NO: 34 .
  • sequence of the light chain variable region of the reference antibody may be selected from the amino acid sequence shown in any one of the following groups or a variant thereof: SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO: 46; the sequence of the heavy chain variable region of the reference antibody may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 48, SEQ ID NO: 50 and SEQ ID NO: 52.
  • the antibodies, antigen-binding fragments or variants thereof described herein may comprise antibody light chains or fragments thereof.
  • the light chain may include a light chain variable region, and the light chain variable region may include LCDR1, and the amino acid sequence of the LCDR1 may be selected from the amino acid sequence shown in any one of the following group or Variants: SEQ ID NO: 4 and SEQ ID NO: 18.
  • the light chain variable region may include LCDR2, and the amino acid sequence of the LCDR2 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 5 and SEQ ID NO: 19.
  • the light chain variable region may include LCDR3, and the amino acid sequence of the LCDR3 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 6 and SEQ ID NO: 20.
  • the light chain variable region of the antibody, antigen-binding fragment or variant thereof may comprise LFR1, and the amino acid sequence of the LFR1 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof : SEQ ID NO: 10, SEQ ID NO: 24 and SEQ ID NO: 35.
  • the light chain variable region may include LFR2, and the amino acid sequence of the LFR2 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 11 and SEQ ID NO: 25.
  • the light chain variable region may include LFR3, and the amino acid sequence of the LFR3 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 12 and SEQ ID NO: 26.
  • the light chain variable region may include LFR4, and the amino acid sequence of the FR4 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 13, SEQ ID NO: 27, and SEQ ID NO:36.
  • sequence of the light chain variable region may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO: 46 .
  • the antibodies, antigen-binding fragments or variants thereof described herein may comprise antibody heavy chains or fragments thereof.
  • the light chain may include a heavy chain variable region, and the heavy chain variable region may include HCDR1, and the amino acid sequence of the HCDR1 may be selected from the amino acid sequences shown in any one of the following groups or Variants: SEQ ID NO: 7, SEQ ID NO: 21 and SEQ ID NO: 32.
  • the variable region of the heavy chain may comprise HCDR2, and the amino acid sequence of the HCDR2 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 8, SEQ ID NO: 22 and SEQ ID NO:33.
  • variable region of the heavy chain may include HCDR3, and the amino acid sequence of the HCDR3 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 9, SEQ ID NO: 23, and SEQ ID NO:34.
  • the heavy chain variable region of the antibody, antigen-binding fragment or variant thereof may include HFR1, and the amino acid sequence of the HFR1 may be selected from the amino acid sequences shown in any one of the following groups or variants thereof : SEQ ID NO: 14, SEQ ID NO: 28 and SEQ ID NO: 37.
  • the variable region of the heavy chain may include HFR2, and the amino acid sequence of the HFR2 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 15, SEQ ID NO: 29, and SEQ ID NO:38.
  • the heavy chain variable region may include HFR3, and the amino acid sequence of the HFR3 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 16, SEQ ID NO: 30, and SEQ ID NO:39.
  • the variable region of the heavy chain may include HFR4, and the amino acid sequence of the HFR4 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 17, SEQ ID NO: 31, and SEQ ID NO:40.
  • sequence of the variable region of the heavy chain may be selected from the amino acid sequence shown in any one of the following groups or a variant thereof: SEQ ID NO: 48, SEQ ID NO: 50, and SEQ ID NO: 52 .
  • the amino acid sequence of LCDR1 in the antibody or antigen-binding fragment thereof described herein may include SEQ ID NO: 4 or its variant; the amino acid sequence of LCDR2 may include SEQ ID NO: 5 or its variant ;
  • the amino acid sequence of LCDR3 may include SEQ ID NO: 6 or its variant; and the amino acid sequence of HCDR1 may include SEQ ID NO: 7 or its variant; the amino acid sequence of HCDR2 may include SEQ ID NO: 8 or its variant;
  • the amino acid sequence of HCDR3 may include SEQ ID NO: 9 or a variant thereof.
  • the antibody or antigen-binding fragment thereof may include antibody 25C5-2 or an antibody having the same LCDR1-3 and HCDR1-3 as it.
  • the amino acid sequence of LFR1 in the antibody or antigen-binding fragment thereof described in this application may include SEQ ID NO: 10 or its variant; the amino acid sequence of LFR2 may include SEQ ID NO: 11 or its variant; the amino acid sequence of LFR3 may include SEQ ID NO: 12 or its variant; the amino acid sequence of LFR4 may include SEQ ID NO: 13 or its variant; and the amino acid sequence of HFR1 may include SEQ ID NO: 14 or its variant; the amino acid sequence of HFR2 may include SEQ ID NO: 15 or a variant thereof; the amino acid sequence of HFR3 may include SEQ ID NO: 16 or a variant thereof; the amino acid sequence of HFR4 may include SEQ ID NO: 17 or a variant thereof.
  • the antibody or antigen-binding fragment thereof may include antibody 25C5-2 or antibodies having the same LFR1-4 and HFR1-4.
  • the light chain of the antibody or antigen-binding fragment thereof described herein may include a light chain variable region, and the amino acid sequence of the light chain variable region may include SEQ ID NO: 42 or a variant thereof ;
  • the heavy chain may comprise a heavy chain variable region, the amino acid sequence of the heavy chain variable region may include SEQ ID NO: 48 or a variant thereof.
  • the antibody or antigen-binding fragment thereof may include antibody 25C5-2 or an antibody having the same light chain variable region and heavy chain variable region as the same.
  • the antibody described in this application may be 25C5-2.
  • the amino acid sequence of LCDR1-3 of antibody 25C5-2 is shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively;
  • the amino acid sequence of LFR1-4 is SEQ ID NO: 10, SEQ respectively ID NO: 11, SEQ ID NO: 12 and SEQ ID NO: 13;
  • VL amino acid sequence is shown in SEQ ID NO: 42;
  • HCDR1-3 amino acid sequences are shown in SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9;
  • the amino acid sequences of HFR1-4 are shown in SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16 and SEQ ID NO: 17, respectively;
  • the amino acid sequence of VH is shown in SEQ ID NO: 48.
  • the antibody 25C5-2 may be scFv, and the scFv is VL-VH (that is, VL is connected to the N-terminus of VH through the linker peptide), wherein the amino acid sequence of the linker peptide may be as SEQ ID NO: 54 shows.
  • the amino acid sequence of the scFv may be as shown in SEQ ID NO: 56.
  • the antibody described in this application may be 10H10-1.
  • the amino acid sequence of LCDR1-3 of antibody 10H10-1 is shown in SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20 respectively;
  • the amino acid sequence of LFR1-4 is SEQ ID NO: 24 and SEQ respectively ID NO: 25, SEQ ID NO: 26 and SEQ ID NO: 27 are shown;
  • the amino acid sequence of VL is shown in SEQ ID NO: 44;
  • the amino acid sequences of HCDR1-3 are shown in SEQ ID NO: 21 and SEQ ID NO: 22 and SEQ ID NO: 23;
  • the amino acid sequences of HFR1-4 are shown in SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30 and SEQ ID NO: 31;
  • the amino acid sequence of VH is shown in SEQ ID NO: 50.
  • the antibody 10H10-1 may be scFv, and the scFv is VL-VH (that is, VL is connected to the N-terminus of VH through the linker peptide), wherein the amino acid sequence of the linker peptide may be as SEQ ID NO: 54 shows.
  • the amino acid sequence of the scFv may be as shown in SEQ ID NO: 58.
  • the antibody described in this application may be 16F10.
  • the amino acid sequences of LCDR1-3 of antibody 16F10 are shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively;
  • the amino acid sequences of LFR1-4 are SEQ ID NO: 35, SEQ ID NO :11, SEQ ID NO:12 and SEQ ID NO:36;
  • VL amino acid sequence is shown as SEQ ID NO:46;
  • HCDR1-3 amino acid sequences are shown as SEQ ID NO:32, SEQ ID NO:33 and SEQ ID NO: 34;
  • the amino acid sequences of HFR1-4 are shown in SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39 and SEQ ID NO: 40 respectively;
  • the amino acid sequence of VH is shown in SEQ ID NO :52 shown.
  • the antibody 16F10 may be scFv, and the scFv is VL-VH (that is, VL is connected to the N-terminus of VH through the linker peptide), wherein the amino acid sequence of the linker peptide may be as SEQ ID NO:54 shown.
  • the amino acid sequence of the scFv may be as shown in SEQ ID NO: 60.
  • the present application provides a fusion protein comprising the antibody, antigen-binding fragment or variant thereof.
  • the fusion protein may be a chimeric antigen receptor (CAR), which may include the antibody and T cell signaling molecule described in the present application.
  • CAR may include domains such as a CD19 binding domain, a transmembrane domain, a hinge region, a costimulatory domain, and an intracellular signal transduction domain.
  • the antibody may be a single chain antibody.
  • the antibody may comprise the amino acid sequence shown in SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 60 or a functional variant thereof.
  • the single chain antibody may include 25C5-2, the amino acid sequence of which is shown in SEQ ID NO: 56.
  • the amino acid sequence of LCDR1-3 of single-chain antibody 25C5-2 is shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively; the amino acid sequence of VL is shown in SEQ ID NO: 42; HCDR1-
  • the amino acid sequence of 3 is shown in SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively; the amino acid sequence of VH is shown in SEQ ID NO: 48.
  • the single-chain antibody may include 10H10-1, and its amino acid sequence is shown in SEQ ID NO: 58.
  • the amino acid sequence of LCDR1-3 of single-chain antibody 10H10-1 is shown in SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20 respectively; the amino acid sequence of VL is shown in SEQ ID NO: 44; HCDR1-
  • the amino acid sequence of 3 is shown in SEQ ID NO: 21, SEQ ID NO: 22 and SEQ ID NO: 23 respectively; the amino acid sequence of VH is shown in SEQ ID NO: 50.
  • the single-chain antibody may include 16F10, and its amino acid sequence is shown in SEQ ID NO: 60.
  • the amino acid sequences of LCDR1-3 of single-chain antibody 16F10 are shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively; the amino acid sequence of VL is shown in SEQ ID NO: 46; HCDR1-3
  • the amino acid sequence is shown in SEQ ID NO: 32, SEQ ID NO: 33 and SEQ ID NO: 34 respectively; the amino acid sequence of VH is shown in SEQ ID NO: 52.
  • the CD19 binding domain may comprise an antibody, antigen-binding fragment or variant that specifically binds CD19.
  • the antibodies, antigen-binding fragments or variants thereof described herein may comprise antibody light chains or fragments thereof.
  • the light chain may include a light chain variable region, and the light chain variable region may include LCDR1, LCDR2, and LCDR3.
  • the amino acid sequence of the LCDR1 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 4 and SEQ ID NO: 18.
  • the amino acid sequence of the LCDR2 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 5 and SEQ ID NO: 19.
  • the amino acid sequence of the LCDR3 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 6 and SEQ ID NO: 20.
  • sequence of the light chain variable region may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 42, SEQ ID NO: 44 and SEQ ID NO: 46 .
  • the light chain may include a heavy chain variable region, and the heavy chain variable region may include HCDR1, and the amino acid sequence of the HCDR1 may be selected from the amino acid sequences shown in any one of the following groups or Variants: SEQ ID NO: 7, SEQ ID NO: 21 and SEQ ID NO: 32.
  • variable region of the heavy chain may comprise HCDR2, and the amino acid sequence of the HCDR2 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 8, SEQ ID NO: 22 and SEQ ID NO:33.
  • the variable region of the heavy chain may include HCDR3, and the amino acid sequence of the HCDR3 may be selected from the amino acid sequence shown in any one of the following group or a variant thereof: SEQ ID NO: 9, SEQ ID NO: 23, and SEQ ID NO:34.
  • sequence of the variable region of the heavy chain may be selected from the amino acid sequence shown in any one of the following groups or a variant thereof: SEQ ID NO: 48, SEQ ID NO: 50, and SEQ ID NO: 52 .
  • the CAR may include a hinge region, which may connect the antibody and the transmembrane domain.
  • the hinge region may be selected from CD8, whose amino acid sequence is shown in SEQ ID NO: 62; or it may be selected from IgG4, whose amino acid sequence is shown in SEQ ID NO: 64.
  • the CAR may include a transmembrane domain.
  • the transmembrane domain may be selected from the ⁇ , ⁇ , or ⁇ chain of the T cell receptor, CD28, CD3e, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86 , CD134, CD137 and CD154 and other polypeptides.
  • the transmembrane domain may be CD8-1, which may include the amino acid sequence shown in SEQ ID NO: 66 or a functional variant thereof; it may also be CD8-2, which may contain SEQ ID NO : The amino acid sequence shown in 68 or a functional variant thereof.
  • the CAR may include a costimulatory domain.
  • the costimulatory domain may be selected from polypeptides such as CD28, 4-1BB, OX40, and ICOS.
  • the costimulatory domain may be 4-1BB, which may contain the amino acid sequence shown in SEQ ID NO: 70 or a functional variant thereof; it may also be OX40, which may contain SEQ ID NO: 72. Shown amino acid sequence or functional variants.
  • the CAR may include a label detection signal
  • the label detection signal may be a fluorescent protein.
  • GFP GFP
  • RFP RFP
  • YFP YFP
  • the label detection signal may be located at the C-terminal of the CAR.
  • the CAR may include a Kozak sequence, the nucleotide sequence of which is shown in SEQ ID NO:1.
  • the Kozak sequence may be located at the N-terminus of the CAR.
  • the CAR may include a leader sequence whose nucleotide sequence is shown in SEQ ID NO: 2 (the nucleotide sequence does not include the Kozak sequence).
  • the leader sequence may be located at the N-terminus of the CAR.
  • the CAR of the present application may include a Kozak sequence, a leader sequence, a CD19 binding domain, a transmembrane domain, a costimulatory domain, and an intracellular signaling domain in sequence from the N-terminus.
  • the CAR described in this application may include the Kozak sequence, the leader sequence, the CD19 binding domain, the transmembrane domain, the costimulatory domain, the intracellular signaling domain, and the label detection signal in sequence from the N-terminus .
  • the CAR described in this application may be CAR25C5-2, the amino acid sequence of LCDR1-3 is shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively; the amino acid sequence of VL is SEQ ID NO: 42; the amino acid sequences of HCDR1-3 are shown in SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9, respectively; the amino acid sequence of VH is shown in SEQ ID NO: 48; VH and VL
  • the sequence of the connecting peptide between them is shown in SEQ ID NO: 54; the nucleotide sequence of its Kozak sequence is shown in SEQ ID NO: 1; the amino acid sequence of its leader sequence is shown in SEQ ID NO: 3; its hinge The amino acid sequence of the region is shown in SEQ ID NO: 62; the amino acid sequence of its transmembrane domain is shown in SEQ ID NO: 66; the amino acid sequence of its costimulatory domain is shown in SEQ ID NO: 70; its CD3 ⁇ cell
  • the CAR described in this application may be CAR10H10-1, and the amino acid sequence of LCDR1-3 is shown in SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 20, respectively; the amino acid sequence of VL is SEQ ID NO: 44; the amino acid sequences of HCDR1-3 are shown in SEQ ID NO: 21, SEQ ID NO: 22 and SEQ ID NO: 23 respectively; the amino acid sequence of VH is shown in SEQ ID NO: 50; VH and VL
  • the amino acid sequence of the connecting peptide is shown in SEQ ID NO: 54; the nucleotide sequence of its Kozak sequence is shown in SEQ ID NO: 1; the amino acid sequence of its leader sequence is shown in SEQ ID NO: 3;
  • the amino acid sequence of the hinge region is shown in SEQ ID NO: 62; the amino acid sequence of its transmembrane domain is shown in SEQ ID NO: 66; the amino acid sequence of its costimulatory domain is shown in SEQ ID NO: 70; its CD3 ⁇ The amino
  • the CAR described in this application may be CAR16F10, and the amino acid sequences of LCDR1-3 are shown in SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6, respectively; the amino acid sequence of VL is SEQ ID NO: 46; the amino acid sequence of HCDR1-3 is shown in SEQ ID NO: 32, SEQ ID NO: 33 and SEQ ID NO: 34 respectively; the amino acid sequence of VH is shown in SEQ ID NO: 52; between VH and VL
  • the amino acid sequence of the connecting peptide is shown in SEQ ID NO: 54; the nucleotide sequence of its Kozak sequence is shown in SEQ ID NO: 1; the amino acid sequence of its leader sequence is shown in SEQ ID NO: 3; its hinge region
  • the amino acid sequence is shown in SEQ ID NO: 62; the amino acid sequence of its transmembrane domain is shown in SEQ ID NO: 66; the amino acid sequence of its costimulatory domain is shown in SEQ ID NO: 70; its CD3 ⁇ cell
  • the present application provides isolated one or more nucleic acid molecules, which can encode the antibodies, antigen-binding fragments or variants described herein, and/or, encode the fusion protein.
  • the isolated nucleic acid molecule encoding the antibody of the present application may comprise the nucleic acid sequence shown in SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59 or a functional variant thereof.
  • the nucleic acid molecules described in this application may be isolated.
  • the isolated nucleic acid is a nucleic acid molecule prepared by recombinant DNA technology.
  • the present application provides one or more vectors, which may contain one or more nucleic acid molecules described in the present application.
  • the vector may be PXC17.4 or pCDNA3.4.
  • the PXC17.4 or pCDNA3.4 vector may include the nucleic acid sequence shown in SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59 or a functional variant thereof.
  • the vector may also contain other genes, such as marker genes that allow selection of the vector in appropriate host cells and under appropriate conditions.
  • the vector may also contain expression control elements that allow the coding region to be correctly expressed in a suitable host. Such control elements are well known to those skilled in the art.
  • the expression control sequence may include promoters, ribosome binding sites, enhancers, and other control elements that regulate gene transcription or mRNA translation.
  • the expression control sequence is an adjustable element.
  • the specific structure of the expression control sequence may vary according to the function of the species or cell type, but usually contains 5'untranscribed sequences and 5'and 3'untranslated sequences involved in transcription and translation initiation, such as TATA box, Cap sequence, CAAT sequence, etc.
  • the 5' non-transcriptional expression control sequence may comprise a promoter region, and the promoter region may comprise a promoter sequence for transcriptional control of functionally linked nucleic acids.
  • One or more nucleic acid molecules described herein can be operably linked to the expression control element.
  • the vector may include, for example, a plasmid, cosmid, virus, bacteriophage, or other vectors commonly used in, for example, genetic engineering.
  • the present application provides one or more cells, which may comprise one or more nucleic acid molecules described herein or one or more vectors described herein.
  • the cells may be selected from PBMC, CD4, CD8, NK and other cells.
  • each or each cell may contain one or one vector described herein.
  • each or each cell may contain multiple (eg, 2 or more) or multiple (eg, 2 or more) vectors described herein.
  • the vector can be introduced into immune effector cells.
  • the vector described in the present application can be introduced into the cells by methods known in the art.
  • the vector described in this application can be introduced into the cells by methods known in the art, such as electroporation, lipofectamine transfection (lipofectamine 2000, Invitrogen), and the like.
  • electroporation lipofectamine transfection (lipofectamine 2000, Invitrogen), and the like.
  • electrical transduction can be performed by Bio-Rad's electrical transduction tool.
  • transduction can be performed by Gibco's transfection kit.
  • the present application provides a method for preparing the antibody, antigen-binding fragment or variant thereof, and/or the fusion protein described in the present application, the method may include An antigen-binding fragment or variant thereof, and/or the fusion protein described herein under the conditions for expressing the cells described herein may further comprise harvesting the antibody, antigen-binding fragment or variant thereof, and/or , The fusion protein.
  • composition pharmaceutical use
  • the present application provides a pharmaceutical composition, which may comprise the antibody described herein, the antigen-binding fragment or variant thereof, the nucleic acid molecule described herein, the carrier described herein, or the The cells and/or fusion proteins described herein, and optionally a pharmaceutically acceptable adjuvant.
  • the pharmaceutically acceptable adjuvants may include buffers, antioxidants, preservatives, low molecular weight polypeptides, proteins, hydrophilic polymers, amino acids, sugars, chelating agents, counterions, metal complexes and/or nonionic surfaces Active agent, etc.
  • the pharmaceutical composition may be formulated for oral administration, intravenous administration (eg, intravenous injection, IV), intramuscular administration (eg, intramuscular injection, IM), the original in the tumor site Site administration, inhalation, rectal administration, vaginal administration, transdermal administration (eg, subcutaneous injection, IC) or administration via subcutaneous depot.
  • intravenous administration eg, intravenous injection, IV
  • intramuscular administration eg, intramuscular injection, IM
  • the original in the tumor site Site administration inhalation
  • rectal administration vaginal administration
  • transdermal administration eg, subcutaneous injection, IC
  • administration via subcutaneous depot e.g, subcutaneous injection, IC
  • the present application provides the antibody, antigen-binding fragment or variant thereof, and/or the use of the fusion protein in the preparation of a medicament for preventing or treating a disease or disorder, wherein the medicament is used for Treatment of tumors and autoimmune diseases.
  • the present application provides the antibody, antigen-binding fragment or variant thereof, and/or the fusion protein, which treats tumors and autoimmune diseases.
  • the present application provides a method for treating tumors and autoimmune diseases, comprising administering the antibody, antigen-binding fragment or variant thereof, and/or the fusion protein to a patient.
  • the tumor is selected from any one of the group consisting of B-cell subtype non-Hodgkin's malignant lymphoma (NHL), Burkitt's lymphoma, multiple myeloma, pre-B Acute lymphoblastic leukemia and other malignant lung tumors derived from early B-cell precursors, common acute lymphocytic leukemia, T chronic lymphocytic leukemia, hairy cell leukemia, non-acute lymphoblastic leukemia, Fahrenheit macroglobulin blood Disease, prolymphocytic leukemia, plasmacytoma, osteosclerotic myeloma, plasmacytic leukemia, monoclonal gammopathy (MGUS), smoldering multiple myeloma (SMM), chronic multiple myeloma (IMM) ), Hodgkin's malignant lymphoma, gastric cancer, liver cancer, leukemia, kidney tumor, lung cancer, small intestine cancer, bone cancer,
  • NHL B
  • the present application provides a method for inhibiting the biological activity of CD19 protein, which comprises administration of the antibody described herein, antigen-binding fragment or variant thereof, the nucleic acid molecule described herein, the The carrier, the cell described in this application and/or the fusion protein described in this application.
  • the present application provides the antibody, antigen-binding fragment or variant thereof, the nucleic acid molecule described herein, the vector described herein, the cell described herein, and/or the The application of the fusion protein described above in the preparation of reagents for diagnosis or detection of tumors.
  • the reagent for diagnosing or detecting tumors can specifically recognize CD19 protein and/or cancer cells bearing CD19 protein.
  • the reagents for diagnosing or detecting tumors can be diagnosed in vitro by methods such as enzyme-linked immunoassay, chemiluminescence, and immunoturbidimetry.
  • the detection can be performed by enzyme-linked immunosorbent assay, using the tumor marker CD19 protein as a stationary phase, and competing with the sample to be tested for the antibody described in this application.
  • the reagent for diagnosing or detecting tumors can react with a substrate of horseradish peroxidase to develop a color for diagnosis of tumors.
  • Each mouse was then injected subcutaneously with 1 mL of Ramos cell solution for immunization.
  • the fourth immunization was performed, the immunization was performed with the Ramos cell solution, and 1 mL of Ramos cell solution was injected subcutaneously into each mouse for immunization.
  • the eyeball blood was taken and the serum antibody titer was detected by ELISA.
  • mice that produce antibodies that specifically bind to CD19
  • the sera of the immunized mice were tested by ELISA as described by Fishwild et al. (1996).
  • the mice whose serum antibody dilution reached more than 10 5 after immunization with recombinant CD19 protein in Example 1.2 were taken, and their spleen was removed after being sacrificed by neck removal.
  • the spleen was crushed and separated using a 70 ⁇ m sieve (corning) to obtain a single
  • the B cells and SP2/0 cells were mixed at a ratio of 1:10, and the B cells and SP2/0 cells were fused into hybridoma cells by means of PEG (purchased from Sigma).
  • the fused cells were dispensed into 96-well cell culture plates in an amount of 200 ⁇ L per well, for a total of 30 96-well cell culture plates.
  • the 96-well cell culture plate was cultured in a 5% CO 2 cell incubator (Thermo 150i) at 37°C, and then a fusion cell line secreting highly active antibodies was screened by ELISA as described by Fishwild et al. (1996).
  • the plate was washed 5 times with PBS/Tween, and 100 ⁇ L of goat-anti-human IgG polyclonal antibody conjugated with horseradish peroxidase (HRP) was added to each well and incubated at 37°C for 30 minutes. After washing 5 times with PBS/Tween, 100 ⁇ L of TMB color developing solution (Shandong Zibo Yunqiao Biotechnology Co., Ltd.) was added to each well. After incubation at 37° C.
  • HRP horseradish peroxidase
  • Three anti-CD19 murine antibodies with different affinities and binding epitopes were screened by hybridoma fusion technology and named 25C5-2, 10H10-1 and 16F10 respectively. Sequencing by Sanger high-throughput sequencing technology (see Tsiatis A, C, Norris-Kirby A, Rich R, G, and others.
  • VL-VH connecting peptide between the VL and VH is artificially synthesized, and its nucleotide sequence is shown in SEQ ID NO:53.
  • nucleotide sequences of VL and VH of the three strains of antibodies that can specifically bind to CD19 obtained by sequencing in the previous step are artificially synthesized, and then connected first to construct the CD19 antibody in scFv format.
  • the 25C5-2 antibody first synthesize its VL, whose nucleotide sequence is shown in SEQ ID NO: 41; then synthesize the VL-VH linking peptide, whose nucleotide sequence is shown in SEQ ID NO: 53 Then, its VH is synthesized, and its nucleotide sequence is shown in SEQ ID NO: 47.
  • the nucleotide sequences of VL, VL-VH linking peptide and VL are connected end to end to obtain the complete 25C5-2scFv sequence.
  • the nucleotide sequence is shown in SEQ ID NO: 55.
  • the 16F10 antibody first synthesize its VL, whose nucleotide sequence is shown in SEQ ID NO: 45; then synthesize the VL-VH connecting peptide, whose nucleotide sequence is shown in SEQ ID NO: 53; then Synthesize its VH, and its nucleotide sequence is shown in SEQ ID NO: 51.
  • the nucleotide sequences of VL, VL-VH connecting peptide and VL are connected end to end to obtain the complete 16F10scFv sequence.
  • the nucleotide sequence is shown in SEQ ID NO:59.
  • the scFv gene synthesized in the previous step was amplified by E. coli to extract the plasmid, digested with BamHI and SaiL, and then ligated into the expression vector PXC17.4, etc., electroporation was performed using Bio-Rad's electrical transduction tool, and the expression vector was introduced into CHO The cells are expressed, and then the expression of the antibody is detected.
  • the CD19 antibody prepared in Example 1 was detected by ELISA. Take 100 ⁇ g of CD19 protein (purchased from acro), add 300 ⁇ L of ultrapure water (purified water meter purchased from PALL) to fully dissolve, and obtain a CD19 protein dilution with a concentration of 0.33 ⁇ g/ ⁇ L. A 96-well test plate was coated with 100 ng per well.
  • the antibodies 16F10, 25C5-2, and 10H10-1 prepared in Example 1 were used for detection, and FMC-63 (Merck, selection MAB1794) was used as a positive control (all anti-CD19 positive controls used in all examples of this application were It is FMC-63.
  • FMC-63 Merck, selection MAB1794.
  • scfv nucleotide sequence please refer to CN201180067173.X SEQ ID NO.14, and the amino acid sequence is SEQ ID NO.20), without adding primary antibody or secondary antibody as a negative control.
  • the diluted test plate was incubated at 37°C for 30 minutes.
  • the plate was washed 5 times, 280 ⁇ L each time. After the plate was washed, the plate was gently patted several times to remove the residual washing solution. Then, add the prepared goat anti-human secondary antibody dilution solution (the goat anti-human secondary antibody was purchased from abcam and diluted with PBS at a ratio of 1:10000) according to the amount of 100 ⁇ L per well. After incubating at 37°C for 30 minutes, the plate was washed . After washing the plate, add TMB color developing solution according to 100 ⁇ L of each well, incubate at 37°C for 5 minutes and add 2M sulfuric acid stop solution according to the amount of 50 ⁇ L per well to stop the reaction.
  • TMB color developing solution according to 100 ⁇ L of each well
  • 2M sulfuric acid stop solution according to the amount of 50 ⁇ L per well to stop the reaction.
  • the CD19 antibody was diluted with PBS according to the following gradient.
  • the specific operation is as follows: take the antibodies 16F10, 10H10-1 and 25C5-2 prepared in Example 1 and dilute them to 50 ⁇ g/mL, 10 ⁇ g/mL, 5 ⁇ g/mL, 2.5 ⁇ g/mL and 1.25 ⁇ g/mL respectively. 200 ⁇ L was added to the cell pellet collected by centrifugation to resuspend the cells. After reacting at 4° C. for 1 hour, the cells were collected by centrifugation and washed three times with PBS.
  • FITC-labeled goat anti-mouse antibody Abcam Anti-Mouse IgG H&L (FITC) ab6785
  • PBS dilution 500 ⁇ L of FITC-labeled goat anti-mouse was added to each detection tube Resuspend the cells in the antibody dilution, and add 500 ⁇ L LITC-labeled goat anti-mouse antibody dilution to the FITC-labeled goat anti-mouse antibody control group.
  • wash the cells three times with PBS as described above Finally, resuspend and wash the centrifuged cells with 200 ⁇ L PBS for flow cytometry.
  • the flow detection voltage is set according to the following steps: After a sufficient amount of sheath liquid is filled in the flow sheath liquid barrel, the flow cytometer (BD verse) is preheated for 20 minutes, the flow detection software is opened, and the FSC/ adhesion to the SSC, FSC and SSC detection Videos in FIG appropriate detection gate, the amount of the detection cell 10 set the detection threshold of 4, FSC-H and then draw a second detector detecting FIG FIGS-a FSC, defined
  • the detection cells on the second detection chart come from P1 gate, and set the appropriate P2 gate on the second detection chart, set the third detection chart COUNT and FITC-A, define the detection data of the third picture from P2 gate After the related test chart is drawn, set the detection voltage with the control NALM-6 cells so that the NALM-6 cells are displayed at the center of the first test chart.
  • start Test NALM-6 cells collect data and set up a control group, save the test voltage and related parameters, and then start the test sample test, and record the related data.
  • the results of 16F10, 10H10-1, 25C5-2 antibody concentration of 5 ⁇ g/mL and FMC63 concentration of 0.025 ⁇ g/mL are plotted. The results are shown in FIG. 2.
  • Marker used in electrophoresis was purchased from full-type gold, catalog number: DM201, lot: K51027, and 5 ⁇ L of each sample was added.
  • Use concentrated gel (5% concentrated gel, 2mL, purified water 1.4mL, 30% Acr-Bis 0.33mL, 1M pH8.8 Tris 0.25mL, 12% SDS (sodium dodecyl sulfonate) 0.02mL, 10% Ammonium persulfate 0.02ml, TEMED (tetramethyldiethylamine) 0.002mL) was concentrated, the voltage was 100V during concentration; use separation gel (10% concentrated gel, 5mL, purified water 1.3mL, 30% Acr-Bis 1.7mL, 1M pH8.8Tris 1.9mL, 12% SDS (sodium dodecyl sulfonate) 0.05mL, 10% ammonium persulfate 0.05mL, TEMED (tetramethyldie
  • the film transfer was performed at a constant voltage of 100V, and the film transfer time was 45 minutes.
  • the polyvinylidene fluoride (PVDF) membrane was placed in a 5% skimmed milk powder solution (PBST solution configuration) for 1 hour, washed 3 times with PBST solution, and washed slowly on a side swing shaker for about 5 minutes each time.
  • the CD19 antibodies 10H10-1, 25C5-1 and the positive control FMC-63 obtained in Example 1 were diluted with PBST to a concentration of 20 ⁇ g/mL and reacted with 5% skim milk-blocked PVDF membrane for 1 hour at room temperature. Then wash with PBST three times, each time on the side shaker and shake slowly for about 5 minutes.
  • NALM-6 cells Take the same NALM-6 cells as in Example 3, collect NALM-6 cells into a 15ml centrifuge tube, centrifuge at 400g for 5 minutes to collect the cells, discard the supernatant, and use the same volume as the discarded supernatant
  • the cells collected by centrifugation were resuspended in PBS buffer solution, and after 3 repetitions, the cells were resuspended with 10 mL of PBS buffer solution.
  • the washed cell suspension was then divided into flow detection tubes, 1 mL per tube. Reserve a tube as a negative control.
  • CD19 antibodies 10H10-1 and 25C5-2 Dilute the CD19 antibodies 10H10-1 and 25C5-2 to be tested to a concentration of 200 ⁇ g/mL in PBS, and then dilute them at the ratios of 1:20, 1:80, 1:320, 1:1280, and 1:5120 respectively.
  • the cells were collected by centrifugation at 4°C for 5 minutes at a speed of 400g, and 1mL of PBS buffer solution pre-cooled to 4°C was added.
  • the flow detection voltage is set according to the following steps: After a sufficient amount of sheath liquid is filled in the flow sheath liquid barrel, the flow cytometer (BD verse) is preheated for 20 minutes, the flow detection software is opened, and the FSC/ adhesion to the SSC, FSC and SSC detection Videos in FIG appropriate detection gate, the amount of the detection cell 10 set the detection threshold of 4, FSC-H and then draw a second detector detecting FIG FIGS-a FSC, defined
  • the detection cells of the second detection chart come from P1 gate, and set the appropriate P2 gate on the second detection chart, set the third detection chart COUNT and FITC-A, define the detection data of the third picture from P2 gate, After the relevant detection chart is drawn, set the detection voltage with the control NALM-6 cells so that the NALM-6 cells are displayed in the center of the first detection chart. After the FITC-A detection signal is between 10-10 2 , start to detect NALM -6 cells, collect data to set up a control group, save the test voltage and related parameters,
  • the obtained anti-CD19scfv and different functional regions form a CAR structure and then the CAR structure is obtained by gene synthesis (the schematic diagram of the CAR structure is shown in Figure 5)
  • nucleotide sequence of the leader is shown in SEQ ID NO. 2; the nucleotide sequence of the hinge region (Hinge) is shown in SEQ ID NO. 61, and the nucleotide sequence of the transmembrane structure (TM) is shown in SEQ ID NO.65, 4-1BB nucleotide sequence is shown in SEQ ID NO.69, OX40 nucleotide sequence is shown in SEQ ID NO.71, CD3zeta nucleotide sequence is shown in SEQ ID NO.73 As shown.
  • the anti-CD19scfv obtained through screening in this application was constructed with 10H10-1 (SEQ ID NO.57) and 25C5-2 (SEQ ID NO.55) as examples, and the positive drug CAR-T (anti-CD19scfv (FMC-63 (Merck))
  • Synthetic genes are amplified by the large intestine, and plasmids are extracted. They are digested with BamHI and SaiL and then ligated into expression vectors. The plasmids are amplified by stabl3 to prepare plasmids for constructing CAR-T cells
  • the constructed anti-CD19CAR-T expression vector was prepared according to the amount of 3.3 ⁇ g corresponding to 4 ⁇ 10 6 T cells.
  • the electrotransformation conditions were followed to collect T cells after electroporation according to the program set together, and the CAR-T cell positive rate and CAR- were detected in 24 hours. T cells kill vitality.
  • NALM-6 cells were washed 4 times with washing solution (1 ⁇ PBS+20 mM Hepes). After the final wash, resuspend the cells in complete medium and adjust the cell density to 8 ⁇ 10 4 cell/mL.
  • target cells are resuspended, an appropriate amount of cell suspension is immediately centrifuged, and the supernatant is taken as a background test well.
  • the fluorescence value was measured by HTRF method (excitation light 340 nm, emission light 615 nm).
  • Cell killing rate (%) (Test well reading-Spontaneous release well reading) / (Maximum release well reading-Spontaneous release well reading) ⁇ 100

Abstract

L'invention concerne un anticorps se fixant spécifiquement à CD19 ou son fragment de fixation à un antigène, l'anticorps se fixant à une protéine CD19 présentant 3,5μg/mL ou moins de IC50. Elle concerne aussi les applications de l'anticorps ou du fragment se fixant à un antigène en vue de la préparation d'un médicament.
PCT/CN2019/122486 2018-12-03 2019-12-02 Anticorps cd19 et ses applications WO2020114358A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201811465547.3 2018-12-03
CN201811465547 2018-12-03
CN201910740771.7 2019-08-12
CN201910740771 2019-08-12

Publications (1)

Publication Number Publication Date
WO2020114358A1 true WO2020114358A1 (fr) 2020-06-11

Family

ID=70945072

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/122486 WO2020114358A1 (fr) 2018-12-03 2019-12-02 Anticorps cd19 et ses applications

Country Status (2)

Country Link
CN (1) CN111253487B (fr)
WO (1) WO2020114358A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112390894A (zh) * 2019-08-12 2021-02-23 广东东阳光药业有限公司 嵌合抗原受体及其应用
KR102393776B1 (ko) * 2020-12-30 2022-05-04 (주)이노베이션바이오 Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체
CN117616048A (zh) * 2021-07-09 2024-02-27 先声再明医药有限公司 Cd19抗体及其应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105950645A (zh) * 2016-01-11 2016-09-21 灏灵赛奥（天津）生物科技有限公司 Car-cd19抗原受体的人源化融合基因片段、其构建方法及应用
CN106117366A (zh) * 2016-06-24 2016-11-16 安徽未名细胞治疗有限公司 一种cd19特异性嵌合抗原受体及其编码基因、应用
CN106536564A (zh) * 2014-06-02 2017-03-22 美国卫生和人力服务部 靶向cd‑19的嵌合抗原受体
CN106800601A (zh) * 2017-01-19 2017-06-06 广东昭泰体内生物医药科技有限公司 一种嵌合抗原受体及其应用
CN106922147A (zh) * 2014-08-28 2017-07-04 朱诺治疗学股份有限公司 Cd19特异性抗体和嵌合抗原受体
CN107312091A (zh) * 2017-05-02 2017-11-03 重庆精准生物技术有限公司 靶向人cd19抗原的人源化单克隆抗体
CN107759700A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd19抗原的转基因t细胞及其制备方法与应用
CN108047332A (zh) * 2018-01-15 2018-05-18 浙江阿思科力生物科技有限公司 以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
CN108330133A (zh) * 2017-01-20 2018-07-27 上海恒润达生生物科技有限公司 靶向cd19嵌合抗原受体并对其双重修饰的方法及其用途
US10125193B2 (en) * 2014-02-14 2018-11-13 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902338B2 (en) * 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10125193B2 (en) * 2014-02-14 2018-11-13 Board Of Regents, The University Of Texas System Chimeric antigen receptors and methods of making
CN106536564A (zh) * 2014-06-02 2017-03-22 美国卫生和人力服务部 靶向cd‑19的嵌合抗原受体
CN106922147A (zh) * 2014-08-28 2017-07-04 朱诺治疗学股份有限公司 Cd19特异性抗体和嵌合抗原受体
CN105950645A (zh) * 2016-01-11 2016-09-21 灏灵赛奥（天津）生物科技有限公司 Car-cd19抗原受体的人源化融合基因片段、其构建方法及应用
CN106117366A (zh) * 2016-06-24 2016-11-16 安徽未名细胞治疗有限公司 一种cd19特异性嵌合抗原受体及其编码基因、应用
CN106800601A (zh) * 2017-01-19 2017-06-06 广东昭泰体内生物医药科技有限公司 一种嵌合抗原受体及其应用
CN108330133A (zh) * 2017-01-20 2018-07-27 上海恒润达生生物科技有限公司 靶向cd19嵌合抗原受体并对其双重修饰的方法及其用途
CN107312091A (zh) * 2017-05-02 2017-11-03 重庆精准生物技术有限公司 靶向人cd19抗原的人源化单克隆抗体
CN107759700A (zh) * 2017-10-18 2018-03-06 银丰生物工程集团有限公司 靶向cd19抗原的转基因t细胞及其制备方法与应用
CN108047332A (zh) * 2018-01-15 2018-05-18 浙江阿思科力生物科技有限公司 以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用

Also Published As

Publication number Publication date
CN111253487B (zh) 2024-02-02
CN111253487A (zh) 2020-06-09

Similar Documents

Publication Publication Date Title
CN113603785B (zh) 新的间皮素抗体和包含其的组合物
WO2017049452A1 (fr) Anticorps entièrement humain contre cd137 humain et son utilisation
US10906965B2 (en) Methods of treating autoimmune disease or chronic inflammation wtih antibodies that bind peptidoglycan recognition protein 1
JP2022510253A (ja) 抗－４－１ｂｂ抗体およびその用途
WO2020114358A1 (fr) Anticorps cd19 et ses applications
WO2016039321A1 (fr) Anticorps spécifique de cellules cancéreuses, agent anticancéreux et méthode de détection du cancer
TWI830151B (zh) 抗GPRC5DxBCMAxCD3三特異性抗體及其用途
CN107108734B (zh) 单克隆抗gpc-1抗体和其用途
WO2019086574A1 (fr) Molécules de liaison à l'antigène cd47 et cd33
CN115386007A (zh) 抗gprc5d抗体、其制备方法与用途
WO2021143914A1 (fr) Anticorps anti-ox40, son procédé de production et son application
Li et al. Validation of glypican-3-specific scFv isolated from paired display/secretory yeast display library
WO2023045370A1 (fr) Anticorps monoclonal ciblant tigit
CN112048019A (zh) 抗人cd47单克隆抗体
CN113683697B (zh) 抗b7-h3抗体、其制备方法及用途
WO2022166700A1 (fr) Procédé d'inhibition de la croissance de cellules tumorales basé sur ccdc112
WO2023179716A1 (fr) Anticorps anti-cd3, son procédé de préparation et son utilisation
TWI830774B (zh) 抗cd47抗體及其應用
WO2024012434A1 (fr) Anticorps, fragment de liaison à l'antigène de celui-ci, et leur utilisation pharmaceutique
WO2023134766A1 (fr) Anticorps ciblant cd25, son procédé de préparation et son utilisation
WO2024061170A1 (fr) Anticorps anti-guanylate cyclase humaine, kit et utilisation de celui-ci
WO2023236844A1 (fr) Anticorps bispécifique ciblant her2 et pd-l1, son procédé de préparation et son utilisation
US20240132579A1 (en) Vegfa-binding molecules
WO2023125349A1 (fr) Anticorps anti-gucy2c et son application
CN117561278A (zh) 抗trem2人源化抗体、其抗原结合片段及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19894020

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19894020

Country of ref document: EP

Kind code of ref document: A1